熱門資訊> 正文
AbbVie认为第三季度，IPR&D和里程碑费用的全年影响是负面的
2025-10-04 04:55
- AbbVie (NYSE:ABBV) said it will incur a negative impact of $1.50 to GAAP and non-GAAP diluted earnings per share in Q3 due to acquired IPR&D and milestones expense of $2.7B.
- As a result, the company now sees Q3 adjusted diluted earnings per share of $1.74-$1.78. Consensus is $3.27.
- AbbVie also said that its full-year EPS guidance range is now $10.38-$10.58. Consensus is $11.97.
More on AbbVie
- AbbVie: Wins Accumulating While We Wait For Next BD Steps
- AbbVie For Healthy Dividend Growth
- AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
- AbbVie and Calico win FDA fast track tag for kidney drug
- INCY and ABBV lead S&P 500 healthcare gainers in Q3; MOH and ALGN lag
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
